Madanat Y, Savona M, Sekeres M, Platzbecker U, Santini V, Fenaux P, Diez-Campelo M, Valcárcel D, Berry T, Dougherty S, Shah S, Sun L, Wan Y, Huang F, Navada S, Komrokji R, Zeidan A. CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs). Journal Of The National Comprehensive Cancer Network 2024, 22 DOI: 10.6004/jnccn.2023.7228.Peer-Reviewed Original Research